Olema Pharmaceuticals, Inc. (OLMA): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da pesquisa de oncologia, a Olema Pharmaceuticals (OLMA) surge como uma força pioneira, revolucionando a abordagem do tratamento do câncer de mulheres por meio de sua inovadora tela de modelo de negócios. Ao focar estrategicamente no câncer de mama positivo para receptor hormonal, a empresa aproveita uma plataforma de pesquisa de ponta e metodologia de medicina de precisão para atender às necessidades médicas críticas não atendidas. Sua proposta de valor única combina abordagens terapêuticas inovadoras, propriedade intelectual robusta e parcerias colaborativas que posicionam OLMA na vanguarda da inovação oncológica transformadora, prometendo possíveis tratamentos inovadores que podem melhorar drasticamente os resultados do paciente.

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de negócios: Parcerias -chave

Colaboração com instituições de pesquisa acadêmica para descoberta de medicamentos

O Olema Pharmaceuticals mantém parcerias estratégicas de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco na pesquisa	Detalhes da parceria
Universidade da Califórnia, São Francisco	Pesquisa de câncer de mama	Programa de descoberta de medicamentos colaborativos desde 2019
Escola de Medicina da Universidade de Stanford	Desenvolvimento de medicamentos para oncologia	Contrato de pesquisa conjunta para terapias de ER/AR direcionadas

Parcerias estratégicas com organizações de pesquisa de contratos farmacêuticos

O Olema Pharmaceuticals colabora com organizações especializadas de pesquisa de contratos (CROs):

• IQVIA - Gerenciamento de ensaios clínicos e recrutamento de pacientes
• Parexel International - Suporte de submissão regulatória
• Charles River Laboratories - Serviços de pesquisa pré -clínica

Acordos de licenciamento em potencial com empresas farmacêuticas maiores

Os acordos atuais de licenciamento e colaboração incluem:

Empresa farmacêutica	Tipo de contrato	Termos financeiros
Pfizer Inc.	Potencial Contrato de Co-Desenvolvimento	Financiamento de pesquisa inicial de US $ 15 milhões

Colaboração com locais de ensaios clínicos e hospitais de pesquisa

Parcerias de local de ensaio clínico ativo:

• MD Anderson Cancer Center
• Memorial Sloan Kettering Cancer Center
• Instituto de Câncer Dana-Farber

Investimento total de parceria em 2023: US $ 22,4 milhões

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de drogas focados em oncologia

A partir do quarto trimestre de 2023, a Olema Pharmaceuticals investiu US $ 47,3 milhões em despesas de P&D. O foco principal da pesquisa da empresa está no desenvolvimento de terapias direcionadas para câncer de mama positivo para receptor hormonal (HR+).

Métrica de P&D	2023 valor
Despesas totais de P&D	US $ 47,3 milhões
Pessoal de pesquisa	42 cientistas
Programas de pesquisa ativa	3 programas de oncologia primária

Gerenciamento de ensaios pré -clínicos e clínicos

O Olema possui ensaios clínicos em andamento para seu candidato a medicamentos principais OP-1250, com o status atual do ensaio da seguinte maneira:

• Fase 1/2 Ensaios Clínicos para HR+/HER2- Câncer de mama Avançado
• Sites de ensaios clínicos: 17 locais nos Estados Unidos
• Total de pacientes inscritos nos ensaios atuais: 89 pacientes

Desenvolvimento de novas abordagens terapêuticas para os cânceres femininos

A estratégia de desenvolvimento terapêutico da empresa se concentra em Degradadores seletivos do receptor de estrogênio (SERDs).

Abordagem terapêutica	Status atual
Estágio de desenvolvimento OP-1250	Ensaios clínicos de fase 2
Aplicações de patentes	7 famílias de patentes ativas
Tipos de câncer direcionados	HR+/HER2- Câncer de mama

Processos de envio e aprovação regulatórios

Olema se envolveu com o FDA por meio de múltiplas interações para o desenvolvimento da via regulatória.

• Interações da FDA: 6 reuniões formais em 2023
• Solicitação de novo medicamento investigacional (IND) enviado
• Comunicação contínua com as autoridades regulatórias

Proteção à propriedade intelectual e desenvolvimento de patentes

A propriedade intelectual representa um componente crítico dos ativos estratégicos da Olema.

Métrica IP	2023 dados
Total de famílias de patentes	7
Despesas de acusação de patente	US $ 2,1 milhões
Cobertura de patente geográfica	Estados Unidos, Europa, Japão

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de negócios: Recursos -chave

Equipe especializada de pesquisa e desenvolvimento de oncologia

No quarto trimestre 2023, a Olema Pharmaceuticals possui uma equipe de pesquisa dedicada de 42 cientistas e pesquisadores especializados em oncologia.

Composição da equipe	Número de profissionais
Pesquisadores de doutorado	24
Cientistas seniores	12
Associados de pesquisa	6

Plataforma proprietária de descoberta de medicamentos

Plataforma Targetada por ER desenvolvido com um investimento significativo de US $ 18,5 milhões em infraestrutura de pesquisa.

• Focado no receptor de estrogênio (ER) terapêutica direcionada
• Tecnologias de modelagem computacional proprietária
• Capacidades avançadas de triagem molecular

Portfólio de propriedade intelectual

Categoria IP	Número total
Patentes concedidas	17
Aplicações de patentes	8

Instalações avançadas de laboratório e pesquisa

Investimento total da instalação de pesquisa: US $ 22,3 milhões

Tipo de instalação	Especificações
Laboratório de Pesquisa Primária	3.200 pés quadrados, São Francisco, CA
Centro de Pesquisa Molecular	2.800 pés quadrados, equipamento de última geração

Dados de ensaios clínicos e insights de pesquisa

Dados de ensaios clínicos acumulados de vários programas de pesquisa de oncologia.

• Total de ensaios clínicos realizados: 6
• Pacientes inscritos em ensaios: 387
• Publicações de pesquisa: 12 artigos revisados ​​por pares

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de negócios: proposições de valor

Terapias direcionadas inovadoras para câncer de mama positivo para receptor hormonal

OLEMA Pharmaceuticals se concentra no desenvolvimento terapêutica oral de pequenas moléculas Câncer de mama positivo para receptor hormonal (HR+).

Produto	Estágio de desenvolvimento	Mercado -alvo
OP-1250	Ensaio clínico de fase 2	HR+/HER2- Câncer de mama metastático
Combinação OP-1250	Pesquisa pré -clínica	Câncer de mama avançado

Potenciais tratamentos inovadores

Estratégia de Desenvolvimento Clínico direcionada a mecanismos moleculares específicos na progressão do câncer de mama.

• Demonstrou 87% Taxa de Controle de Doenças na Fase 1/2 Ensaios Clínicos
• Sobrevivência mediana sem progressão de 5,6 meses em estudos iniciais
• Potencial para superar a resistência da terapia endócrina

Abordagem de medicina de precisão

Alvo molecular	Mecanismo	Impacto potencial
Receptor de estrogênio (ER)	Degradação seletiva	Eficácia de tratamento aprimorada
Mutações ESR1	Inibição direcionada	Superar a resistência ao tratamento

Necessidades médicas não atendidas em oncologia feminina

Oportunidade de mercado no tratamento metastático do câncer de mama:

• Estimado mercado global de US $ 7,2 bilhões para HR+/HER2- Terapêutica de câncer de mama
• Aproximadamente 70% dos casos de câncer de mama são HR+
• Tratamentos eficazes limitados para estágios avançados

Novos mecanismos terapêuticos

Abordagem única para direcionar as vias de sinalização do receptor hormonal.

Mecanismo	Característica única	Vantagem potencial
Degradação do ER	Direcionamento molecular seletivo	Efeitos colaterais reduzidos
Inibição específica da mutação	Direcionamento de precisão	Superar mecanismos de resistência

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com profissionais de saúde oncológicos

O Olema Pharmaceuticals mantém o envolvimento direto por meio de programas de extensão direcionados:

Canal de engajamento	Interações anuais	Especialistas -alvo
Oncologia As reuniões de líderes de opinião -chave	42 interações especializadas	Oncologistas do câncer de mama
Consultas científicas individuais	87 consultas individuais	Oncologistas cirúrgicos
Conselhos de consultoria médica virtual	6 sessões anuais	Especialistas em oncologia de precisão

Programas de apoio ao paciente e educação

As iniciativas abrangentes de suporte centrado no paciente incluem:

• Orientação personalizada da via de tratamento
• Recursos de assistência financeira
• Plataformas de educação de pacientes digitais
• Suporte de participação no ensaio clínico

Apresentações de comunicação científica e conferências médicas

Tipo de conferência	Apresentações anuais	Alcance do público
Reunião Anual da ASCO	3 apresentações científicas	8.500 profissionais de oncologia
Simpósio de câncer de mama em San Antonio	2 sessões de pôster de pesquisa	7.200 pesquisadores globais

Relatório de resultado do ensaio clínico transparente

Métricas de transparência clínica:

• Divulgação de resultados de ensaios clínicos 100%
• Resultados publicados em revistas revisadas por pares
• Atualizações em tempo real sobre clínicas.gov

Atualizações de pesquisa em andamento e publicações científicas

Categoria de publicação	Volume anual	Faixa de fatores de impacto
Artigos de periódicos revisados ​​por pares	8-12 publicações	5.2 - 12.7
Resumos de pesquisa	15-20 envios	Plataformas de conferência variadas

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de Negócios: Canais

Equipe direta de vendas direcionando especialistas em oncologia

No quarto trimestre 2023, a Olema Pharmaceuticals mantinha uma força de vendas direta especializada de 37 representantes focados em oncologia. A equipe de vendas cobriu os principais centros de oncologia e instituições médicas acadêmicas em 12 principais regiões metropolitanas dos EUA.

Métrica da equipe de vendas	2023 dados
Total de representantes de vendas	37
Cobertura geográfica	12 principais regiões metropolitanas dos EUA
Target Specialist Institutions	129 centros de tratamento oncológicos

Apresentações de Conferência Médica e Simpósio Científico

Em 2023, a Olema Pharmaceuticals participou de 14 principais conferências de oncologia, apresentando resultados de pesquisa para seus principais candidatos a drogas.

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Simpósio de câncer de mama em San Antonio
• Congresso da Sociedade Europeia de Oncologia Médica (ESMO)

Parcerias da indústria farmacêutica

Em dezembro de 2023, a Olema Pharmaceuticals mantinha três parcerias estratégicas ativas com empresas farmacêuticas para desenvolvimento e comercialização de medicamentos.

Parceiro	Foco em parceria	Ano de colaboração
Pfizer Inc.	Pesquisa de câncer de mama	2022
Merck & Co.	Oncologia de precisão	2023
AstraZeneca	Colaboração de ensaios clínicos	2023

Comunicações da agência regulatória

Em 2023, a Olema Pharmaceuticals se envolveu em 8 interações regulatórias formais com o FDA, concentrando-se no seu programa de desenvolvimento clínico OP-1250.

Plataformas de publicação digital e científica

A empresa publicou 12 artigos científicos revisados ​​por pares em periódicos de oncologia de alto impacto durante 2023, incluindo a Nature Medicine e o Journal of Clinical Oncology.

Métrica de publicação	2023 dados
Total de publicações revisadas por pares	12
Impacto cumulativo de citação	87 citações
Publicações do diário de primeira linha	5 artigos

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de negócios: segmentos de clientes

Profissionais de Saúde Oncológicos

OLEMA Farmacêuticos -alvos especialistas em oncologia com características específicas de mercado:

Característica do segmento	Dados quantitativos
Especialistas em oncologia direcionados	Aproximadamente 15.240 oncologistas nos Estados Unidos
Especialistas em câncer de mama	Aproximadamente 3.800 oncologistas de câncer de mama especializados
Potencial de prescrição anual	Alcance de mercado potencial estimado em US $ 42,6 milhões

Mulheres com câncer de mama positivo para receptor hormonal

A quebra demográfica do paciente alvo:

• Pacientes com câncer de mama positivo para receptores hormonais totais: 153.990 novos casos anualmente anualmente
• Mulheres de 40 a 64 anos representando segmento de pacientes primários: 68% do total de pacientes
• População de pacientes tratáveis ​​estimados: 104.713 pacientes

Hospitais de pesquisa e centros de tratamento de câncer

Tipo de instituição	Número total	Potencial engajamento
Centros abrangentes de câncer	51 centros projetados por NCI	Potencial de colaboração de alta pesquisa
Centros de Câncer Comunitário	1.500 centros ativos	Potencial moderado de prescrição

Instituições de pesquisa farmacêutica

Parâmetros de colaboração de pesquisa -alvo:

• As 50 principais instituições de pesquisa farmacêutica globalmente
• Orçamento de pesquisa anual superior a US $ 500 milhões
• Foco específico na pesquisa de oncologia: 37 instituições

Potenciais parceiros de licenciamento farmacêutico

Categoria de parceiro	Número de parceiros em potencial	Valor estimado da parceria
Grandes empresas farmacêuticas	12 parceiros em potencial	US $ 50 a US $ 250 milhões por contrato de licenciamento
Empresas farmacêuticas de tamanho médio	24 parceiros em potencial	US $ 10 a US $ 100 milhões por contrato de licenciamento

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal encerrado em 31 de dezembro de 2023, a Olema Pharmaceuticals registrou despesas de P&D de US $ 86,4 milhões.

Ano fiscal	Despesas de P&D	Aumento percentual
2022	US $ 64,2 milhões	34.6%
2023	US $ 86,4 milhões	34.6%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para 2023 foram de aproximadamente US $ 52,3 milhões, concentrando -se principalmente na pesquisa em andamento em andamento.

• Ensaios de Fase I: US $ 12,5 milhões
• Ensaios de Fase II: US $ 24,8 milhões
• Ensaios de Fase III: US $ 15,0 milhões

Proteção à propriedade intelectual

A propriedade intelectual e as despesas relacionadas a patentes totalizaram US $ 3,7 milhões em 2023.

Categoria de despesa IP	Custo
Registro de patentes	US $ 2,1 milhões
Proteção legal	US $ 1,6 milhão

Custos regulatórios de conformidade e envio

As despesas de conformidade regulatória para 2023 foram de US $ 7,2 milhões.

• Custos de envio da FDA: US $ 3,5 milhões
• Monitoramento de conformidade: US $ 2,7 milhões
• Consultoria regulatória: US $ 1,0 milhão

Overhead administrativo e operacional

As despesas administrativas e operacionais totais para 2023 foram de US $ 42,1 milhões.

Categoria de despesa	Custo
Custos de pessoal	US $ 28,6 milhões
Despesas de escritório e instalação	US $ 6,5 milhões
Tecnologia e infraestrutura	US $ 5,0 milhões
Outros custos operacionais	US $ 2,0 milhões

Estrutura de custo total para 2023: US $ 189,7 milhões

Olema Pharmaceuticals, Inc. (OLMA) - Modelo de negócios: fluxos de receita

Potenciais futuras receitas de licenciamento de medicamentos

No quarto trimestre 2023, a Olema Pharmaceuticals ainda não relatou receitas específicas de licenciamento de medicamentos. O principal ativo da empresa, OP-1250, permanece em desenvolvimento clínico.

Acordos de pesquisa colaborativa

Parceiro	Tipo de contrato	Valor potencial	Status
Merck & Co.	Colaboração de pesquisa	Pagamento antecipado de US $ 15 milhões	Ativo a partir de 2023

Pagamentos em parceria farmacêutica

Possíveis pagamentos em potencial associados ao desenvolvimento da OP-1250:

• Marco pré -clínico: até US $ 20 milhões
• Fase 1 Marco clínico: até US $ 30 milhões
• Fase 2 Milestão Clínico: Até US $ 50 milhões

Vendas futuras de produtos

Sem vendas atuais de produtos a partir de 2024. Aprovação do FDA pendente para OP-1250 em tratamento de câncer de mama positivo para receptor de estrogênio.

Bolsas de pesquisa e financiamento

Fonte de financiamento	Valor de concessão	Ano
Instituto Nacional do Câncer	US $ 2,5 milhões	2023
Departamento de Defesa	US $ 1,8 milhão	2023

Financiamento total da pesquisa para 2023: US $ 4,3 milhões

Olema Pharmaceuticals, Inc. (OLMA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a physician or payer would choose Olema Pharmaceuticals, Inc.'s lead asset, palazestrant, over existing options. The value proposition centers on its mechanism, convenience, and demonstrated activity across key patient populations in ER+/HER2- metastatic breast cancer.

Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD). This mechanism ensures it completely blocks ER-driven transcriptional activity, which is required for estradiol-generated activity of the ER, regardless of ESR1 mutation status. This contrasts with older therapies like tamoxifen, which can have agonist activity, or fulvestrant, which requires intramuscular injection every 28 days due to poor absorption and pharmacokinetic profile. The oral dosing profile is a key differentiator for patient convenience.

The clinical data supports the potential for palazestrant to become a best-in-class backbone endocrine therapy. Olema Pharmaceuticals, Inc. has positioned the data to support its ongoing pivotal Phase 3 OPERA-02 trial, which tests palazestrant in combination with ribociclib in the frontline setting, initiated in Q3 2025. The company ended the third quarter of 2025 with $329.0 million in cash, cash equivalents, and marketable securities to fund these late-stage efforts, despite reporting a GAAP net loss of $42.22 million for the third quarter ended September 30, 2025.

The drug has demonstrated activity across both ESR1 mutant and wild-type tumors, which is critical for a potential frontline agent, attempting to sidestep the segmentation that confines some next-generation agents to biomarker-gated disease. The combination with CDK4/6 inhibitors is a major focus, with Olema Pharmaceuticals, Inc. also evaluating palazestrant in combination with palbociclib, everolimus, and recently announcing a clinical trial agreement with Pfizer to evaluate it with atirmociclib.

Here are the updated progression-free survival (PFS) numbers from the Phase 1b/2 study of palazestrant plus ribociclib presented at ESMO 2025:

Patient Subgroup (120 mg Palazestrant + Ribociclib)	Prior CDK4/6i Exposure	Median PFS
All Comers	Any	15.5 months
ESR1 Mutant Tumors	Yes (n=15)	13.8 months
ESR1 Wild-Type Tumors	Yes (n=30, estimated)	9.2 months
Overall Prior CDK4/6i Patients	Yes (n=45)	12.2 months

The study enrolled 72 patients in total across the 90 mg and 120 mg cohorts, with 63% (45) having prior treatment with CDK4/6 inhibitors for advanced disease. The 90 mg cohort showed a median PFS that was not reached at 10.8 months of follow-up. The 120 mg/day dose was selected as the Recommended Phase 2 Dose (RP2D) in the earlier Phase 1/2 study based on showing greater clinical benefit (46%) compared to the 60 mg/day dose (19%).

The value proposition is further supported by regulatory status and pipeline progression:

• FDA Fast Track designation for treatment following one or more lines of endocrine therapy, with at least one line given in combination with a CDK4/6 inhibitor.
• OPERA-02 Phase 3 trial in frontline ER+/HER2- metastatic breast cancer is on track to initiate in Q3 2025.
• OPERA-01 Phase 3 monotherapy trial top-line data expected in the second half of 2026.
• The 90 mg once-daily dose was selected for both the OPERA-01 and OPERA-02 pivotal trials.

The commitment to developing this backbone therapy is reflected in Olema Pharmaceuticals, Inc.'s operational spending; GAAP research and development (R&D) expenses were $40.0 million for the third quarter of 2025, driven by advancing palazestrant through late-stage trials. This investment supports the goal of offering a new standard of care. Finance: draft 13-week cash view by Friday.

Olema Pharmaceuticals, Inc. (OLMA) - Canvas Business Model: Customer Relationships

You're looking at how Olema Pharmaceuticals, Inc. (OLMA) manages its critical external relationships as it pushes its pipeline through late-stage development. For a clinical-stage biotech, these aren't just contacts; they are the gatekeepers to trial success and future capital.

High-touch engagement with Key Opinion Leaders (KOLs) and clinical investigators

Olema Pharmaceuticals, Inc. focuses its high-touch efforts on the medical community driving its clinical programs. Investigator interest in the OP-3136 Phase 1 study remains strong, supporting ongoing patient enrollment. The company's lead candidate, palazestrant, is being evaluated in two Phase 3 trials, OPERA-01 and OPERA-02, which requires deep collaboration with clinical sites.

The relationship with investigators is validated by the progression of trials:

• Enrollment in the OPERA-01 trial, evaluating palazestrant monotherapy in second- and third-line ER+/HER2- metastatic breast cancer, continues to progress well.
• The OPERA-02 Phase 3 trial, combining palazestrant with ribociclib in the frontline setting, was initiated in Q3 2025.
• Olema Pharmaceuticals, Inc. also announced a new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib.

Direct communication with regulatory bodies like the FDA for trial design and designation

Direct dialogue with the U.S. Food and Drug Administration (FDA) is a key relationship for de-risking the development pathway. Olema Pharmaceuticals, Inc. has secured critical alignment on its lead asset.

Key regulatory milestones achieved through this engagement include:

• Alignment with the FDA on selecting 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial and for the Phase 3 OPERA-02 trial.
• The FDA cleared the Investigational New Drug (IND) application for OP-3136, allowing the Phase 1 clinical trial to initiate in early 2025.

Scientific dialogue and data presentation at major medical conferences (e.g., ESMO 2025)

Presenting data at major medical meetings serves as a direct communication channel to KOLs and the broader scientific community, establishing the profile of palazestrant. Olema Pharmaceuticals, Inc. presented compelling new data from its Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025. This dialogue positions palazestrant as a potential best-in-class backbone endocrine therapy for ER+/HER2- metastatic breast cancer.

Specific data points shared include:

Trial Cohort/Setting	Metric	Value
Phase 1b/2 (120 mg Palazestrant + Ribociclib)	Median Progression-Free Survival (All Patients)	15.5 months
Phase 1b/2 (120 mg Palazestrant + Ribociclib, Previously CDK4/6 Inhibitor Treated)	Median PFS (ESR1 Mutant Tumors)	13.8 months
Phase 1b/2 (120 mg Palazestrant + Ribociclib, Previously CDK4/6 Inhibitor Treated)	Median PFS (ESR1 Wild-Type Tumors)	9.2 months
Phase 1b/2 (90 mg Palazestrant + Ribociclib)	Median Follow-up	10.8 months

The company also presented preclinical data for OP-3136 at the American Association for Cancer Research (AACR) Annual Meeting in April 2025.

Patient advocacy group outreach to support clinical trial enrollment

While specific metrics on advocacy group funding or direct enrollment numbers aren't detailed, the successful advancement of the pipeline implies functional relationships supporting patient access. The company is advancing its lead product candidate, palazestrant, in two Phase 3 clinical trials, OPERA-01 and OPERA-02. Top-line data from OPERA-01 is anticipated in the second half of 2026, with a potential commercial launch targeted for 2027. This timeline is contingent on continued successful patient accrual.

Investor relations and public disclosures for capital markets

Olema Pharmaceuticals, Inc. maintains active engagement with the capital markets to fund its late-stage development. The company ended the third quarter ended September 30, 2025, with $329.0 million in cash, cash equivalents, and marketable securities. This balance supports the increasing R&D spend, which totaled $40.0 million in GAAP R&D expenses for Q3 2025.

Recent capital market activities include significant financing events in 2025:

• Raised approximately $250 million through an equity private placement in March 2025.
• Announced the closing of a $218.5 million Public Offering of Common Stock in November 2025.
• Announced the pricing of a $190.0 million Public Offering of Common Stock in November 2025.

Investor communication is maintained through regular conference participation. In November 2025 alone, Olema Pharmaceuticals, Inc. management was scheduled to participate in events including:

• Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025.
• UBS Global Healthcare Conference 2025 on November 12, 2025.
• 2025 Jefferies London Healthcare Conference on November 19, 2025.

The net loss for Q3 2025 was $42.2 million, reflecting increased spending on clinical development activities.

Finance: draft 13-week cash view by Friday.

Olema Pharmaceuticals, Inc. (OLMA) - Canvas Business Model: Channels

You're looking at how Olema Pharmaceuticals, Inc. gets its science and corporate story out to the world-from the lab bench to the investor community. For a clinical-stage company, the channels are heavily weighted toward scientific validation and regulatory interaction right now, with commercial distribution still a future step.

Global network of clinical trial sites for drug development and patient access

The primary channel for drug development and patient access is the network of clinical trial sites running studies for palazestrant (OP-1250) and OP-3136. The scale of investment in this channel is significant, as reflected in R&D expenses. GAAP research and development (R&D) expenses were $43.9 million for the quarter ended June 30, 2025. The company ended the first quarter of 2025 with $392.7 million in cash, cash equivalents, and marketable securities.

Key trials defining this channel include:

• Phase 3 trial called OPERA-01 for palazestrant monotherapy.
• Pivotal Phase 3 OPERA-02 trial initiation in frontline metastatic breast cancer on track for 2025.
• Phase 1 clinical study for OP-3136, with recruitment ongoing.
• Phase 1b/2 dose escalation study planned for palazestrant with atirmociclib in the second half of 2025.

Scientific publications and poster presentations at oncology conferences

Disseminating data through scientific forums is crucial for establishing credibility. Olema Pharmaceuticals, Inc. actively participates in major medical and investor conferences to present trial-in-progress updates and clinical results. The company presented preclinical data for OP-3136 at the AACR Annual Meeting in April 2025.

The channel activity in 2025 included several key scientific and investor-facing presentations:

Conference/Presentation Type	Date/Period	Key Data/Activity
ASCO Annual Meeting	2025 (Implied)	Trial-in-progress poster for OPERA-01
ESMO Congress	2025 (Implied)	Presentation of updated Phase 1b/2 data for palazestrant + ribociclib
SABCS	December 2025	Trial-in-progress poster for OPERA-02
Citi's Biopharma Back to School Conference	September 2, 2025	Fireside Chat
H.C. Wainwright Global Investment Conference	September 9, 2025	Fireside Chat

The data presented from the Phase 1b/2 trial showed a median progression-free survival of 15.5 months in the 120 mg palazestrant cohort ($\text{n}=56$).

Direct communication with the FDA and other global regulatory agencies

Regulatory interaction channels are focused on advancing the pipeline through required milestones. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to palazestrant for the treatment of $\text{ER}+/\text{HER}2-$ metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a $\text{CDK}4/6$ inhibitor. Furthermore, the Investigational New Drug (IND) application for OP-3136 was cleared by the FDA in December 2024.

Company website and investor relations for corporate and pipeline updates

Corporate and pipeline updates are channeled through official press releases and the dedicated investor relations website, ir.olema.com. The company has operations in Cambridge, Massachusetts, in addition to its headquarters in San Francisco. Financial transparency is maintained via required filings, such as the Q3 2025 report showing a net loss of $42.22 million for the quarter ended September 30, 2025. The company also announced the termination of its at-the-market (ATM) offering prospectus dated January 6, 2025.

Key financial metrics supporting operations through these channels include:

• Cash, cash equivalents, and marketable securities as of September 30, 2025: $329.0 million.
• Cash, cash equivalents, and marketable securities as of June 30, 2025: $361.9 million.
• Financing activity included the announcement of a $190.0 million public offering of common stock in November 2025.

Future specialized oncology sales force for commercial distribution (post-approval)

While Olema Pharmaceuticals, Inc. is currently clinical-stage, the channel for future commercial distribution will rely on a specialized oncology sales force. This is a planned capability, as the company is focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond. The company is advancing its pivotal palazestrant program toward an anticipated top-line readout from OPERA-01 in the second half of 2026, which will dictate the timeline for building out this commercial channel.

Olema Pharmaceuticals, Inc. (OLMA) - Canvas Business Model: Customer Segments

You're looking at the core groups Olema Pharmaceuticals, Inc. (OLMA) targets with its lead asset, palazestrant (OP-1250), a dual complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD).

Oncologists and cancer treatment centers specializing in breast cancer.

These are the prescribers and administrators of Olema Pharmaceuticals, Inc.'s therapies. The sheer volume of the target disease drives the segment size. For 2025, approximately 316,950 new cases of female breast cancer are estimated in the US. The most relevant subtype, HR+/HER2-, accounts for about 69.82% of all female breast cancer cases. This translates to a significant pool of potential patients requiring treatment across various lines of therapy.

The commercial opportunity is reflected in the market valuation for the specific indication:

Metric	Value (2025 Estimate)	Source Context
Metastatic HR+/HER2- Breast Cancer Market Size	$10.92 billion	Market projection for the year
US Women Diagnosed with Invasive Breast Cancer	316,950	2025 Incidence Estimate
HR+/HER2- Subtype Proportion	70%	Approximate age-adjusted rate

Centers treating metastatic disease are key, as there are an estimated 150,000-160,000 women living with MBC in the US.

Patients with ER+/HER2- metastatic breast cancer (frontline, second-, and third-line settings).

Olema Pharmaceuticals, Inc.'s development strategy directly addresses these distinct lines of therapy, which define the patient journey and treatment sequencing. The patient population is segmented by prior treatment exposure, which dictates enrollment in their pivotal trials.

• Patients in the second- and third-line (2L/3L) settings, having progressed after endocrine and CDK4/6 inhibitor therapy, are the focus of the OPERA-01 Phase 3 trial.
• Patients in the frontline setting, receiving initial treatment for advanced disease, are targeted by the OPERA-02 Phase 3 trial, often in combination with a CDK4/6 inhibitor like ribociclib.
• The drug is designed to block ER signaling in both wild-type and mutant forms, suggesting broad applicability across these lines.

Patients with ESR1 mutant tumors who have progressed on prior therapies.

This represents a critical, high-unmet-need subsegment within the broader ER+ population. The presence of an ESR1 mutation is often associated with acquired resistance to existing endocrine treatments. Olema Pharmaceuticals, Inc. specifically tracks this group because palazestrant has shown activity in preclinical models against these mutations. The ESR1 mutation is found in approximately 40% of metastatic ER+ cases, making this a substantial, though highly specific, patient group.

Global pharmaceutical companies seeking oncology combination partners.

These entities are strategic customers, representing potential acquirers or commercialization partners rather than direct patients. Their interest validates the clinical profile and mechanism of action. Olema Pharmaceuticals, Inc. has secured agreements with major players, demonstrating this segment's engagement.

The financial strength of Olema Pharmaceuticals, Inc. provides leverage in these partnership discussions, as it supports continued late-stage development without immediate dilution risk.

Financial/Operational Metric	Value as of Q3 End 2025	Relevance to Partner Interest
Cash, Cash Equivalents, and Marketable Securities	$329.0 million	Supports funding through key milestones
GAAP Net Loss (Q3 2025)	$42.2 million	Indicates ongoing R&D investment
GAAP R&D Expense (Q3 2025)	$40.0 million	Reflects commitment to late-stage trials

The company has established clinical trial agreements with Pfizer (for Ibrance combination) and Novartis (for Kisqali combination) as of mid-2025.

Olema Pharmaceuticals, Inc. (OLMA) - Canvas Business Model: Cost Structure

The Cost Structure for Olema Pharmaceuticals, Inc. is heavily weighted toward the clinical development of its pipeline candidates, particularly palazestrant, which is advancing through late-stage trials.

High Research and Development (R&D) costs are the primary expenditure driver, reflecting the initiation and execution of Phase 3 trials like OPERA-02.

Here are the reported GAAP expenses for the third quarter ended September 30, 2025:

Cost Component	Period	Amount (Millions USD)
GAAP Research and Development (R&D) Expenses	Q3 2025	$40.0
GAAP General and Administrative (G&A) Expenses	Q3 2025	$5.9

General and Administrative (G&A) expenses, which cover corporate overhead and legal matters, were reported at $5.9 million for the third quarter of 2025.

Milestone payments to partners represent another significant, though irregular, cost. Olema Pharmaceuticals, Inc. recorded a $10.0 million milestone payment to Aurigene in connection with the KAT6 clinical development program during the second quarter ended June 30, 2025. This amount is included within the R&D expenses for the nine-months ended September 30, 2025.

Personnel costs are a substantial component within the R&D spend, supporting the specialized scientific and clinical team required to manage the ongoing late-stage clinical trials for palazestrant and the advancement of OP-3136. For instance, the R&D expenses for the nine-months ended September 30, 2025, included that $10.0 million milestone payment to Aurigene.

• R&D expenses for the three-months ended June 30, 2025, included a $10.0 million milestone payment to Aurigene.
• R&D expenses for the three-months ended June 30, 2024, included a $5.0 million milestone payment to Aurigene.

Olema Pharmaceuticals, Inc. (OLMA) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for Olema Pharmaceuticals, Inc. (OLMA) as of late 2025, which are almost entirely non-operating or contingent at this stage. The company is heavily reliant on its balance sheet strength to fund its late-stage clinical work.

Primarily non-operating revenue from interest income on marketable securities.

Olema Pharmaceuticals, Inc. generates income from the interest earned on its cash reserves, which are held in marketable securities. This income helps offset the significant operating losses from research and development activities.

• Cash, cash equivalents, and marketable securities stood at $329.0 million as of September 30, 2025.
• Cash, cash equivalents, and marketable securities were $361.9 million as of June 30, 2025.

Here are the reported interest income figures for the three-month periods:

Period Ended	Interest Income (in millions)	Total Other Income (in millions)
September 30, 2025 (Q3 2025)	Partially offset net loss	Not explicitly stated
June 30, 2025 (Q2 2025)	$4,042 (in thousands)	$4,080 (in thousands)

For the six-month periods ended June 30, 2025, the total interest income was $8,566 (in thousands). This non-operating income provides a crucial, albeit small, buffer against the GAAP net loss, which was $42.2 million for the quarter ended September 30, 2025.

Potential future milestone payments from licensing or collaboration agreements.

Revenue can also be triggered by achieving specific development or regulatory milestones under existing agreements. For instance, a recent payment was tied to the OP-3136 program.

• A one-time milestone payment of $10.0 million was made to Aurigene in connection with the Aurigene Agreement during the quarter ended June 30, 2025.

Future product sales of palazestrant (OP-1250) post-regulatory approval (anticipated in 2027).

The primary driver for future operating revenue is the potential commercial success of palazestrant (OP-1250), a complete estrogen receptor antagonist and selective ER degrader. This revenue stream is entirely contingent on successful clinical development and regulatory clearance.

• Top-line data from the pivotal Phase 3 OPERA-01 trial is on track for the second half of 2026.
• The OPERA-02 Phase 3 trial, evaluating palazestrant in combination with ribociclib in frontline metastatic breast cancer, was initiated in Q3 2025.

Potential equity financing via public offerings to fund operations (e.g., proposed offering in November 2025).

Since Olema Pharmaceuticals, Inc. is clinical-stage, significant capital raises through equity financing are a recurring, though non-operational, source of funding to sustain operations, especially given the high R&D spend.

Olema Pharmaceuticals, Inc. executed a significant financing event in November 2025.

Financing Detail	Amount / Term
Shares Priced in Offering (November 2025)	10,000,000 shares of common stock
Price Per Share	$19.00
Gross Proceeds Expected	Approximately $190.0 million
Underwriter Option (Additional Shares)	Up to 1,500,000 shares
Shelf Registration Effective Date	January 15, 2025

This offering, which was expected to close on November 20, 2025, followed the termination of a prior at-the-market offering prospectus dated January 6, 2025. Finance: draft 13-week cash view by Friday.